Page last updated: 2024-11-01

ofloxacin and Infectious Diseases

ofloxacin has been researched along with Infectious Diseases in 2 studies

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Research Excerpts

ExcerptRelevanceReference
"The population pharmacokinetics of levofloxacin (LVFX), the l-enantiomer of ofloxacin, were studied in 522 subjects, including normal subjects and patients with infectious diseases."7.69Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. ( Hori, R; Kagimoto, N; Nomura, H; Okumura, K; Tanigawara, Y, 1995)
"The population pharmacokinetics of levofloxacin (LVFX), the l-enantiomer of ofloxacin, were studied in 522 subjects, including normal subjects and patients with infectious diseases."3.69Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. ( Hori, R; Kagimoto, N; Nomura, H; Okumura, K; Tanigawara, Y, 1995)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Viale, P1
Scudeller, L1
Cristini, F1
Tanigawara, Y1
Nomura, H1
Kagimoto, N1
Okumura, K1
Hori, R1

Other Studies

2 other studies available for ofloxacin and Infectious Diseases

ArticleYear
Levofloxacin: a suitable option for the infectious disease consultant.
    Journal of chemotherapy (Florence, Italy), 2004, Volume: 16 Suppl 2

    Topics: Anti-Bacterial Agents; Communicable Diseases; Critical Illness; Cross Infection; Humans; Intensive C

2004
Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases.
    Biological & pharmaceutical bulletin, 1995, Volume: 18, Issue:2

    Topics: Age Factors; Bayes Theorem; Clinical Trials as Topic; Communicable Diseases; Humans; Levofloxacin; M

1995